Mural Oncology plc (MURA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mural Oncology plc (MURA) has a cash flow conversion efficiency ratio of -0.335x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.48 Million) by net assets ($55.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Mural Oncology plc for the company's overall valuation and market capitalisation.
Mural Oncology plc - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Mural Oncology plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Mural Oncology plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mural Oncology plc ranked by their cash flow conversion efficiency. See Mural Oncology plc (MURA) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fundamental Global Inc.
NASDAQ:FGNX
|
-0.010x |
|
Malin Corporation plc
IR:MLC
|
-0.004x |
|
TREJHARA SOLUTIONS LIMITED
NSE:TREJHARA
|
0.008x |
|
Royal Orchid Hotel (Thailand) Public Company Limited
BK:ROH
|
-0.003x |
|
Nova Leap Health Corp
V:NLH
|
0.021x |
|
YM Tech Co. Ltd.
KQ:273640
|
0.035x |
|
Jack Chia Industries (Thailand) Public Company Limited
BK:JCT
|
0.022x |
|
Logindo Samudramakmur Tbk
JK:LEAD
|
0.069x |
Annual Cash Flow Conversion Efficiency for Mural Oncology plc (2021–2024)
The table below shows the annual cash flow conversion efficiency of Mural Oncology plc from 2021 to 2024. View today's stock price for Mural Oncology plc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $140.50 Million | $-128.54 Million | -0.915x | -24.26% |
| 2023-12-31 | $263.82 Million | $-194.25 Million | -0.736x | -109.46% |
| 2022-12-31 | $-21.66 Million | $-168.59 Million | 7.785x | -11.16% |
| 2021-12-31 | $-17.88 Million | $-156.67 Million | 8.763x | -- |
About Mural Oncology plc
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cut… Read more